I don't give a continental about Canaccord; its obvious they...

I don't give a continental about Canaccord; its obvious they have been ramping AXP since it listed. That is not the responsibility of AXP Management.

What the Canaccord analysis say, viewed even conservatively and broadly, is that the Aeroform value proposition is exceptional ... Aeroform is far safer, less painful, more convenient and gives users some control over their recuperation in what must be the most confronting of circumstances facing a woman.

For the record, I didn't think capital raising when AXP announced FDA approval last December - my bad. Now all my analysis includes a check of available cash and facilities verses forecast flow with more than 1 years coverage a requirement; my responsibility!!